For protection against dysentery caused by Shigellaflexneri 2a, an in vivo-constructed recombinant plasmid with genes specifying the S. flexneri type and group antigens located near the pro (min 6) and his (min 44) chromosomal markers, respectively, was made and transferred to the galE Salmonella typhi strain Ty2la. Strain Ty2la carrying this recombinant plasmid was shown by immunological and biochemical analyses to express the S. flexneri 2a type and group antigens. Mice immunized with this vaccine strain were found to be protected against challenge with virulent S. flexneri 2a, but not significantly against S. typhi challenge, presumably because synthesis of the Shigell antigens interfered with expression of the typhoid antigens. Elimination of the recombinant plasmid from Ty2la allowed this strain to again express typical S. typhi 0 antigens. Mouse protection against both S. typhi and S. flexneri 2a challenges was achieved with a whole-cell vaccine mixture composed of equal parts of Ty2la and the Ty2la-S. flexneri 2a hybrid strain.
Typhoid and dysentery remain major public health problems in many areas of the world. These diseases are endemic in developing countries due to low levels of sanitation and can periodically cause significant outbreaks of disease in developed nations. During the past 20 years, a high level of bacterial resistance to most of the useful antibiotics has developed and spread among Shigella species. The chemotherapeutic approach to dysentery disease control now appears to be much less effective and more unpredictable.
An important alternative medical measure is the use of vaccines. One vaccine, administered orally, which has shown great potential in protection against typhoid fever is the galactose epimeraseless (galE) mutant of Salmonella typhi Ty21a, isolated and characterized by Germanier and Furer (7) . The Ty2la galE mutant is unable to produce the enzyme UDP galactose-4-epimerase and consequently cannot convert glucose to galactose, a component of Salmonella core oligosaccharide and 0 repeat unit structures. Unless galactose is supplied exogenously, strain Ty2la synthesizes an incomplete cell wall lipopolysaccharide (LPS) lacking the immunogenically important 0 antigens. When grown on galactose-containing medium, however, the organism is able to synthesize typical LPS. Administration of this strain as a live vaccine is possible because of its limited viability in vivo. In the process of synthesizing its 0 antigens, it also accumulates lethal amounts of galactose intracellularly in the form of galactose 1-phosphate and UDP-galactose, and bacterial osmotic lysis occurs. In a study with human volunteers, Ty2la was shown to confer statistically significant protection against typhoid fever when grown under conditions in which its 9,12 0 antigens were synthesized, but not under conditions in which its 0 antigens were not synthesized (8) . The live, attenuated oral vaccine strain Ty2la has also been tested and proven successful in preventing human typhoid fever in a field trial (11) .
Current antidysentery vaccine development is based on the considerations that immunity to shigellosis is serotype specific (i.e., against the LPS) and that a safe, oral vaccine would be most effective. Kopecko et al. (9) have provided genetic and physical evidence that the Shigella sonnei form I surface antigen is encoded by a 180-kilobase-pair (kb) plasmid. Formal et al. (5) used this information to construct a potential vaccine strain by introduction of the form I plasmid into the galE oral vaccine strain Ty2la. This bifunctional vaccine strain protected mice against challenge with either S. typhi or Shigella sonnei (5) and has been shown to protect human volunteers against S. sonnei challenge (1) .
In view of the fact that strain Ty2la can act as a carrier for the form I antigenic determinant(s), it should serve as an oral vaccine system for other enterically acquired diseases as well when appropriate protective antigen genes are introduced. Since many cases of shigellosis in the United States and elsewhere are due to Shigella flexneri serotype 2a, a study was undertaken to develop a similar S. typhi Ty2la derivative oral vaccine that specifies the Shigellaflexneri 2a O antigens to protect against dysentery caused by this Shigella serotype. The construction and preliminary characterization of this Ty21a-S. flexneri 2a hybrid vaccine strain are reported here.
MATERIALS AND METHODS
Media, culture conditions, and conjugal transfer. As described elsewhere (5), minimal medium, PenAssay medium (Difco Laboratoiies), nutrient medium (Difco), MacConkey medium (Difco), and brain-heart infusion medium (BHI; Difco), with or without 1.5% agar (Difco), were used for bacterial growth. For normal supplementation and selection, streptomycin was used at 100 ,g/ml, carbohydrates were used at 0.5%, and amino acids and vitamins were added at 0.1%. For immunization studies, however, growth of the attenuated galE S. typhi Ty2la strain and its derivatives was done in BHI broth containing 0.1% galactose. Virulent organisms for challenge studies were grown in BHI broth. Sterile physiological saline (0.9%) was used for cell washing and suspension of both vaccine and challenge organisms. For conjugal transfer experiments, donor and recipient bacteria were grown to the late exponential phase in stationary PenAssay broth cultures. A 5-ml amount each of donor and recipient cultures were mixed, mating was allowed to occur for 6 to 12 h, and the resulting transconjugants were selected on the appropriate agar medium. Potential transconjugants were then purified on identical selective medium.
Bacterial strains, phage, and Mu-promoted transposition. The bacterial strains used are listed in Table 1 . The S. typhi Ty2la spontaneous pro his Strr mutant was obtained in sequential steps. Initially, a Strr mutant was obtained by plating about 5x 1010 nutrient-broth-grown Ty2la cells onto nutrient agar containing streptomycin (25 p.g/ml). Purified Strr Ty2la cells were sequentially grown in minimal broth containing penicillin (5 ,ug/ml) and plated on glucose minimal agar to select a pro mutant, which was then retreated similarly to obtain a pro his Strr mutant, WR4085.
The procedure for Mu-promoted transposition of genes to a conjugative plasmid has been described in detail previously (4) . Basically, the F'lac::Mu cts62 plasmid was transferred conjugally at 32°C from strain WR2051 to S. flexneri serotype 2a strain WR1078. The resultant S. flexneri strain harboring FPlac::Mu cts62 (WR1079) was grown at 37°C to induce Mu-promoted transposition of S. flexneri chromosomal genes to the F'Iac plasmid and then conjugally mated at 37°C with his pro Escherichia coli and S. typhi recipient strains.
DNA isolation and agarose gel electrophoresis. The conditions and procedures for DNA isolation and electrophoresis have been described previously (2, 5, 9) . Serological studies. Antisera were prepared by immunizing rabbits with live bacterial suspensions. Agglutination tests and agglutination adsorption procedures were conducted by the methods of Edwards and Ewing (3).
Mouse protection assay. The procedures and the ICR mouse strain used have been described in detail (5) . Groups of outbred ICR mice (weighing 13 to 15 g) were inoculated intraperitoneally with 0. LPS analysis. Techniques for extracting LPS and analyzing preparations by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) have been described previously (10) . Basically, LPS from all bacterial strains examined was prepared by the hot phenol-water method of Westphal and Jann (12) . SDS-PAGE was performed on 13.5% acrylamide slab gels with a discontinuous buffer system. Electrophoresed LPS antigens were visualized by silver staining or by immunoblot analysis. During immunoblotting, the antigens were electroblotted, as previously described (9), to nitrocellulose and sequentially reacted with anti-S. flexneri serotype 2a antibody and 125"-labeled staphylococcal protein A. The washed immunoblot was exposed to X-Omat AR film for 24 h at -70°C in a cassette with an intensifying screen (Eastman Kodak).
RESULTS
In vivo construction of recombinant plasmids. In Shigella flexneri serotype 2a, the 0 antigen is determined by two widely separated chromosomal regions (6) . The a or group antigen locus specifying the 0 repeat unit backbone (specifically termed the 3,4 antigen) is encoded by genes located near the his marker at min 44 (6) . The type antigen locus, referred to as type 2, controlling the chemical modification of the 0 repeat unit is located near the pro region of the chromosome in the vicinity of min 6 (6) were obtained from Shigella sonnei form I strain 53G, from E. coli AB1133(pWR90) (strain WR3055), and from Ty2la(pWR90) (strain WR4086) as described previously (9) . Agarose gel electrophoresis of these plasmid preparations against plasmid standards of known size was conducted as described earlier (5) . The direction of electrophoresis is from top to bottom. both Pro and His. Also, plasmid pWR90 was readily maintained in strain WR4086 by growth on a selective minimal medium lacking proline and histidine. These results indicated that these Shigella loci (pro, his, and 0-antigen genes) were part of the same recombinant plasmid, pWR90.
Plasmid analysis. Plasmid DNA was isolated from E. coli K-12 strain WR3055 and S. typhi Ty2la strain WR4086, both carrying pWR90, and analyzed by electrophoresis on agarose gels. The form I plasmid was apparently 180 kb, while plasmid pWR90 appeared to be 195 kb in size whether obtained from E. coli K-12 (Fig. 1, center lane) LPS analysis. To characterize further the surface antigens of parental and genetic hybrid strains, the LPS extracted from several of the previously described strains was subjected to SDS-PAGE analysis as described previously (10) (Fig. 2 and 3) . The LPS isolated from the phenotypically rough E. coli K-12 strain AB1133 was composed of lipid A and an oligosaccharide core, but lacked any core-linked 0 side chains (Fig. 2, lane 1) . The LPS of wild-type Shigella flexneri serotype 2a had core lipid A and a typical ladder of 0 repeat bands (Fig. 2) ; each band represents one additional 0 repeat unit added to the core. The LPS of the E. coli AB1133 hybrid strain carrying pWR90 (Fig. 2, lane 3) showed 0 repeat units of the same molecular mass and chain length (10 to 18) as occurred in the wild-type Shigellaflexneri serotype 2a strain (lane 2). LPS from strain Ty2la grown in the absence of galactose showed the pattern typical of a galE rough strain, with lipid A core only (Fig. 2, lane 4) . However, with LPS from the Ty2la strain carrying pWR90 (WR4086), also grown in medium lacking galactose, a change relative to Ty2la (lane 4) of the lipid A and core bands, which are the predominant bands in this lane, was detected (Fig. 2, lane 5) . The WR4086 LPS bands corresponding to the 0 side chains appeared very faintly, suggesting degradation of this LPS during hot phenol-H20 extraction. Im serotype 2a serum, strain WR4086 was agglutinated to a titer of 1:960 (Table 2 ).
In serum adsorption tests (Table 3 ), all S. flexneri serotype 2a antibodies were removed from the antiserum by strain WR4086 or by the S. flexneri 2a control strain 2457T. Also, S. typhi strain Ty2la or 0901 removed all 9,12-specific antibodies from the homologous antiserum. Strain WR4086, however, failed to remove all of the 9, 12 antibodies from the antityphoid serum, leaving an agglutination titer of 1:120 when tested with the control S. typhi strain 0901.
To determine whether strain WR4086 could regain its ability to synthesize its full complement of typhoid 9, 12 antigenic components, a segregant of WR4086 was selected which had lost pWR90, the recombinant plasmid specifying the Shigella serotype 2a group and type antigens. In serum adsorption studies, segregant strain WR4087 was observed to have lost the ability to neutralize S. flexneri serotype 2a-directed antibodies and to have regained the ability to neutralize all anti-9,12 antibodies (Table 3) .
Mouse protection studies. The ability of various bacterial strains to protect mice against intraperitoneal challenge with virulent S. typhi Ty2 or S. flexneri serotype 2a strains was assessed (Table 4) . Strain Ty2la protected against homologous S. typhi challenge but not against S. flexneri challenge, as expected. S. flexneri 2a strain WR1080 protected against homologous S. flexneri challenge, but 14 of 15 mice died after heterologous challenge. The genetic hybrid Ty2la strain WR4086 provided significant protection against S. flexneri challenge but not against S. typhi challenge. Based on these results, a whole-cell vaccine made up of equal parts of the Ty2la parent and WR4086 was tested to determine whether such a combination vaccine would be suitably In this report, a genetically stable recombinant plasmid, pWR90, that contains two widely separated S. flexneri chromosomal loci responsible for synthesizing the serotype 2a 0 antigen was constructed via Mu-mediated transposition (4). pWR90, found to be about 195 kb in size, was determined by agglutination studies (Tables 2 and 3 ) and LPS analysis ( Fig. 2 and 3 ) to effect the synthesis of S. flexneri 2a 0 antigen in both E. coli K-12 and S. typhi Ty2la hosts. Furthermore, serum adsorption studies showed that cells of Ty21a carrying pWR90 (WR4086) did not express sufficient 9,12 S. typhi somatic antigens to remove the total antibody to these antigens. When strain WR4086 was tested as a vaccine in mice, this strain protected only against challenge by virulent S. flexneri serotype 2a and not against typhoid challenge (Table 4) . Agglutinin adsorption studies (Table 3) of strain WR4086 and its plasmid-free derivative WR4087 indicated that expression of the S. flexneri 2a 0 antigen in Ty2la somehow interfered with normal synthesis or expression of the 9,12 antigens. It seems possible that the 9,12 somatic components are physically covered by the S. flexneri 0-antigen chains in strain WR4086 or that altered 9,12 somatic components are synthesized when the S. flexneri serotype 2a antigens are also produced. However, the fact that the plasmid-free derivative strain WR4087 expressed typical 9,12 antigens indicates that the necessary S. typhi LPS genes remain intact. The inability of strain WR4086 to serve as an antityphoid vaccine is thus due to impaired expression of the typhoid antigenic components. Nevertheless, a combined, whole-cell vaccine mixture consisting of parental Ty2la and WR4086 strains was found to behave as a bifunctional antityphoid and anti-S. flexneri serotype 2a vaccine. Additional studies will be necessary to determine the stability of this vaccine upon lyophilization, its safety in humans, and its efficacy as a potential human vaccine.
The above results raise three important issues. First, it is now apparent that expression of certain heterologous antigens can adversely affect the antityphoid efficacy of a genetic hybrid Ty2la vaccine. Therefore, for use as a bifunctional vaccine, each Ty2la genetic hybrid strain carrying heterologous antigenic determinants, especially 0 antigens, should be assessed for its antityphoid efficacy as well as for protection against the second pathogen. Second, a genetic carrier vaccine strain lacking the 9,12 typhoid somatic antigens and synthesizing primarily the added heterologous determinants is envisioned as being preferable in certain situations (e.g., for use in a population already immunized orally against typhoid fever). Third, humans are the only host normally susceptible to S. typhi infection. Mouse protection tests that use intraperitoneal challenge to assay the efficacy of S. typhi-based vaccines represent a logical first step in determining the antigenic nature and, hence, the vaccine potential of a strain. These tests, however, are necessarily artificial, as they do not mimic the normal route of infection and thus cannot directly reflect the potential value of a vaccine in humans. Development of an animal system that would directly reflect the potential for human use of an S. typhibased vaccine would be highly desirable.
This report and the previous study of Formal et al. (5) suggest that Ty2la or similar attenuated S. typhi strains can serve as carriers of major protective-antigen-producing genes of different pathogens. It is possible that a series of oral vaccines that will protect against many enterically acquired pathogens (e.g., bacterial, viral, and protozoan) can be constructed by using this type of oral vaccine system.
